Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986277 + nivolumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BMS-986277 + nivolumab is a combination immunotherapy regimen under investigation for advanced epithelial tumors, consisting of BMS-986277, a systemically administered recombinant oncolytic virus engineered to express **CD80** and an anti-CD3 bispecific, and **nivolumab**, a monoclonal antibody checkpoint inhibitor targeting PD-1. BMS-986277 aims to activate immune responses in the tumor microenvironment, rendering tumors more susceptible to immune-mediated destruction. Nivolumab enhances T-cell activity by blocking the PD-1/PD-L1 axis. The combination is intended to synergistically increase immune activation and antitumor efficacy, as studied in phase 1/2a clinical trials in metastatic colorectal, prostate, pancreatic, triple-negative breast, ovarian, or urothelial carcinoma[1][4][5].
- Other names
- CD80/αCD3 Oncolytic Virusnivolumab
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD80 (T-lymphocyte activation antigen CD80)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on BMS-986277 + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986277 + nivolumab.